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Abstract
Allogeneic hematopoietic cell transplantation (alloHCT) is a complex, potentially fatal therapy featuring a myriad of
complications. Triggering event(s) of such complications vary significantly, but often a so-called “multi-organ failure”
(MOF) is reported as the leading cause of death. The identification of the exact trigger of MOF is critical towards early and
disease-specific intervention to improve outcome. We examined data from 202 alloHCT patients reported to have died of
MOF from the EBMT registry aiming to determine their exact cause of death focusing on veno-occlusive disease/sinusoidal
obstruction syndrome (VOD/SOS) due to its life-threatening, often difficult to capture yet preventable nature. We identified a
total of 70 patients (35%) for whom VOD/SOS could be considered as trigger for MOF and leading cause of death, among
which 48 (69%) were previously undiagnosed. Multivariate analysis highlighted history of hepatic comorbidity or
gentuzumab use and disease status beyond CR1 as the only significant factors predictive of VOD/SOS incidence (OR= 6.6;
p= 0.001 and OR= 3.3; p= 0.004 respectively). VOD/SOS-related MOF was widely under-reported, accounting for 27%
of deaths attributed to MOF of unknown origin without a previous VOD/SOS diagnosis. Our results suggest most missed
cases developed late VOD/SOS beyond 21 days post-alloHCT, highlighting the importance of the newly revised EBMT
criteria.
Introduction
Sinusoidal obstruction syndrome (SOS), previously known
as veno-occlusive disease (VOD) is a life-threatening
complication observed after hematopoietic cell transplan-
tation (HCT) [1]. It is believed to occur following
endothelial injury due to toxic metabolites generated from
conditioning regimens [2], and its diagnosis is mostly
clinical based on criterion scoring systems [3–5]. VOD/SOS
can develop anytime post-transplant classically within
3 weeks but up to months later with a peak incidence of
around 15% in high risk adult patients [1, 3]. While VOD/
SOS can present as a mild self-resolving disease, around
46% of cases present with aggressive disease leading to
multiorgan failure (MOF) with a mortality exceeding 80%
[6]. Severe VOD/SOS has a very rapid clinical course and
hence a very narrow therapeutic window for intervention
[7], with significant survival advantage associated with
early treatment with defibrotide [8]. Furthermore, prophy-
lactic defibrotide benefits have been established in the
pediatric population but is still under investigation in adults
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[9, 10]. The established criteria, in particular according to
Baltimore carry the risk of underdiagnosing VOD/SOS due
to the 21-day limitation and the obligatory hyperbilir-
ubinemia, not present at diagnosis in 29 and 15% of
pediatric and adult patients, respectively [11]. Accordingly
it is believed by expert opinion that there is a true urgency
for the awareness of VOD/SOS being widely under-
diagnosed, leading to the vague diagnosis of MOF [12].
Transplant patients often have concomitant comorbidities
and their deterioration is usually multifactorial encompass-
ing their original disease, infections, graft-versus-host dis-
ease (GVHD), VOD/SOS, and drug toxicities among other
factors [13]. Some studies have retrospectively reviewed
transplant patients’ labelled cause of death and found major
discrepancies raising concerns about the accuracy of
reported disease burdens [13]. No retrospective studies
however, investigated the incidence of VOD/SOS as an
initiating factor in patients succumbing to MOF to deter-
mine the hidden burden of this disease. The aim of this
study was to quantify the proportion of adult acute leukemia
patients that succumbed to MOF following alloHCT and
who fit the VOD/SOS criteria prior to their deterioration.
For that purpose, we studied a large sample from the Eur-
opean Society for Blood and Marrow Transplantation
(EBMT) registry.
Materials and methods
Study design and data collection
This was a retrospective, registry-based, multicenter ana-
lysis [14]. Data were provided and approved by the EBMT
Acute Leukemia Working Party. The EBMT is a voluntary
collaborating working group of more than 600 transplant
centers that are required to report all consecutive stem cell
transplantations and follow-up once a year, with regularly
performed audits to determine the accuracy of the data.
Since the 1st of January 2003, all transplantation centers
have been required to obtain written informed consent prior
to data registration with the EBMT, as per the Declaration
of Helsinki of 1975.
Eligibility criteria for this analysis included adult patients
(aged >18 years) with acute leukemia who received an
alloHCT between 2010 and 2018 with reported cause of
death being MOF (Supplementary Table 1) anytime post-
transplant.
Patient-related variables collected included recipient and
donor age and gender, patient blood group, history of hepatic
comorbidities and obesity, date of diagnosis, the chronologic
number of the transplant, disease status, Karnofsky perfor-
mance score (KPS) and HCT specific comorbidity index
(HCTI) at time of transplant. Transplant-related factors
included date, conditioning regimen, source of stem cells,
donor type and degree of mismatch, and ex-vivo/in-vivo
manipulation. GVHD-related factors included prophylaxis
and treatment, with onset and grade of GVHD development.
A questionnaire was sent to participating centers for
missing variables in the registry and study-specific vari-
ables. These included the use of gemtuzumab prior to
transplant, VOD prophylaxis use, VOD diagnosis and date
of diagnosis when applicable, weight, bilirubin, creatinine
and liver enzyme levels at transplant and last month before
death, the presence of iron overload, hepatomegaly, and
ascites before death, and results of investigational liver
ultrasounds/biopsies done prior to death when applicable.
These criteria were then used for a posteriori VOD diag-
nosis within the last month before death which has been
reported as MOF.
Definitions
Myeloablative conditioning (MAC) was defined as a regi-
men containing either total body conditioning (TBI) with a
dose equal or greater than 8 Gy, a total dose of oral busulfan
(Bu) greater than 8 mg/kg, or a total dose of intravenous Bu
greater than 6.4 mg/kg. All other regimens were defined as
reduced intensity conditioning (RIC) [15]. Diagnosis and
grading of acute [16] and chronic GVHD [17] were per-
formed by transplant centers using standard criteria. High-
resolution HLA allele typing at loci A, B, C, DRB1, and
DQ was retrieved from the EBMT registry for both the
patient and the donor. Hepatic comorbidity was defined
according to the HCTI definition by Sorror et al. [18].
Endpoints
Endpoints included determining the proportion of patients
that fit at least one VOD/SOS diagnosis scoring system,
including the Baltimore criteria [4], modified Seattle criteria
[5], and classic and late EBMT criteria [3], and how many
were not previously diagnosed with VOD/SOS; along with
identifying risk factors for VOD/SOS development.
Statistical analysis
Patient, disease, and transplant-related characteristics were
compared by using χ2 statistics for categorical variables and
the Mann-Whitney test for continuous variables. Compar-
ison of the outcomes was performed using a logistic model
and results expressed as an odds ratio (OR) with 95%
confidence interval (CI). All tests were two sided. All
analyses were performed using SPSS 24.0 (SPSS Inc,
Chicago, IL, USA)) and R version 3.6.2 (R Core Team. R:
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a language for statistical computing. 2014. R Foundation for
Statistical Computing, Vienna, Austria).
Results
Patient and transplantation characteristics
For the purpose of this analysis, we identified 253 adult
patients, 51 (20%) of which were excluded due to lack of
appropriate data to make or rule out a VOD/SOS diagnosis.
Median age was 50.5 years, ranging from 20 to 73.4 years,
and 58% of patients were males. Patients had acute leuke-
mia (73% acute myeloid leukemia (AML), 24% acute
lymphoblastic leukemia (ALL) & 3% mixed phenotype)
and were reported to the EBMT registry to have died from
MOF. Forty-nine percent of patients underwent transplan-
tation in first complete remission (CR1), 23% in CR2 and
28% had advanced disease. In total, Twelve patients had a
history of hepatic comorbidity, and 8 patients received
gemtuzumab before transplant (Table 1).
Patients were allografted between 2010 and 2018
(median 2015) from a matched sibling (24%), unrelated
(58%), haploidentical (11%), or cord blood (CB) (7%)
donor. Conditioning was MAC in 57% of patients and 28%
underwent TBI. Finally, approximately one-third of the
study population received VOD/SOS prophylaxis, mainly
consisting of ursodiol alone (49%), heparin alone (25%), or
a combination of both (16%). The remaining 10% received
other drugs and combinations (Table 2).
VOD/SOS as primary cause of death
Fourteen patients were initially diagnosed with VOD/SOS,
and an additional 8 were reported by centers after ques-
tionnaires were sent. All remaining patients were reported
as never having VOD. Applying the most common VOD/
SOS scoring systems using data collected from the last
month before MOF-induced death, we identified a total of
70 (35%) patients that fit a VOD/SOS diagnosis, 48 (69%)
of whom were previously undiagnosed (Fig. 1). VOD/SOS
could therefore be considered as a trigger of MOF pro-
gression ultimately leading to death. Twenty-four patients
were diagnosed using the modified Seattle criteria, 11 also
fit the classic EBMT/Baltimore criteria, and 41 patients
were diagnosed using the late EBMT criteria. Five
remaining patients were labeled as VOD/SOS by their
centers but did not meet the criteria for any of these sys-
tems. No post-mortem pathology was available to confirm
the diagnosis.
Univariate analysis comparing patients who died of VOD/
SOS related MOF with non-VOD/SOS related MOF identi-
fied disease status at transplant, donor type and graft cell
source, KPS, the presence of hepatic comorbidity, and the use
of gemtuzumab before transplant or mycophenolate mofetil
(MMF) for GVHD prophylaxis as well as acute GVHD
incidence as significantly different across the two groups
(Tables 1 and 2). In fact, patients with VOD/SOS related
MOF were less likely to be in CR1 or have a KPS >= 90
compared to non-VOD/SOS related MOF, with rates of 35%
vs 56% (p= 0.022) and 58% vs 72% (p= 0.045) respec-
tively; but were more frequently associated with haploiden-
tical or CB transplants, history of hepatic comorbidities, and
gemtuzumab or MMF use with rates of 27% vs 13% (p=
0.013), 16% vs 3% (p= 0.007), 21% vs 4% (p= 0.003), 9%
vs 2% (p= 0.022), and 46% vs 29% (p= 0.02) respectively.
Importantly, there was a strong correlation between MMF use
for GVHD prophylaxis and haploidentical or CB transplan-
tation (p < 0.0001), which were associated with increased
VOD/SOS incidence acting as possible confounders between
the graft type and the choice of GVHD prophylaxis. Inter-
estingly, although there were no differences in overall acute
GVHD grades II-IV & III-IV rates, GVHD grades I-III were
significantly increased in patients with non-VOD/SOS related
MOF (43.1% vs 19.4%) while grade IV GVHD was more
common in the VOD/SOS group (21% vs 10%). This dis-
proportionate increase in grade IV GVHD in the VOD/SOS
group could be explained by a possible misdiagnosis in these
patients due to the overlap in MOF presentation, whereas
patients were wrongly labeled as having severe GVHD and
not VOD/SOS. The significantly lower median survival after
transplant in the VOD/SOS group at 61 days compared to
128 days in the non-VOD/SOS related MOF (p= 0.0005)
could explain the increased incidence of grades I-III GVHD in
the non-VOD/SOS group. In a multivariate analysis using a
stepwise selection of significant and clinically relevant vari-
ables (Table 3), CR1 and the presence of hepatic comorbidity
or gemtuzumab use were the only two significant factors
associated with VOD/SOS incidence with an OR of 0.29
(p= 0.004) and 6.6 (p= 0.001) respectively. Finally, among
patients that fit VOD/SOS diagnosis criteria, 87% had high
bilirubin levels before death, 51% presented with ascites, 36%
with hepatomegaly, and 43 and 29% had weight gain of at
least 2 and 5% of body weight respectively, from transplant
day 0 to death (Supplementary Table 2).
Discussion
VOD/SOS is a life-threatening complication post-alloHCT,
widely believed to be a sequela of treatment induced
endothelial injury [1, 2], with mortality exceeding 80% in
severe cases and a very narrow therapeutic window for
intervention [6, 7]. VOD/SOS diagnosis is mostly clinical
using one of many available diagnostic scoring systems
[3–5], which makes it easy to overlook and requires very
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Table 1 Patient characteristics comparison between VOD-related and non-VOD-related MOF.
no VOD (n= 132) VOD (n= 70) P value Population
(n= 202)
Patient age at transplant (years)







Male 76 (57.6%) 40 (57.1%) 0.95 116 (57.7%)
ABO blood group
A 53 (40.2%) 31 (44.3%) 0.6 83 (41.6%)
B 21 (15.9%) 6 (8.6%) 27 (13.4%)
AB 8 (6.1%) 5 (7.1%) 13 (6.4%)
O 50 (37.9%) 28 (40.0%) 78 (38.6%)
Diagnosis
AML 93 (70.5%) 54 (77.1%) 0.5 147 (72.8%)
ALL 34 (25.8%) 15 (21.4%) 49 (24.3%)
Mixed Phenotype 5 (3.8%) 1 (1.4%) 6 (3%)
AML
de novo 71 (76.3%) 43 (79.6%) 0.65 114 (77.6%)
Secondary AML 22 (23.7%) 11 (20.4%) 33 (22.4%)
Myelodysplasia related changes
Good 12 (15.8%) 7 (15.9%) 0.44 19 (15.8%)
Interm 46 (60.5%) 22 (50.0%) 68 (56.7%)
Poor 18 (23.7%) 15 (34.1%) 33 (27.5%)
Missing 17 10 27
ALL
Ph- B ALL 13 (48.1%) 7 (58.3%) 0.27 20 (51.3%)
Ph+ B ALL 3 (11.1%) 3 (25%) 6 (15.4%)
T ALL 11 (40.7%) 2 (16.7%) 13 (33.3%)
Missing 7 3 10
Status at transplant
CR1 73 (55.7%) 24 (35.3%) 0.022 97 (48.7%)
CR2+ 27 (20.6%) 19 (27.9%) 46 (23.1%)
Advanced 31 (23.7%) 25 (36.8%) 56 (28.1%)
Missing 1 2 3
Status details
Primary Refractory 13 (9.9%) 12 (17.6%) 0.089 25 (12.6%)
CR1 73 (55.7%) 24 (35.3%) 97 (48.7%)
CR2 24 (18.3%) 15 (22.1%) 39 (19.6%)
CR3+ 3 (2.3%) 4 (5.9%) 7 (3.5%)
First relapse 15 (11.5%) 11 (16.2%) 26 (13.1%)
Second relapse or more 3 (2.3%) 2 (2.9%) 5 (2.5%)
Missing 1 2 3
Karnofsky score
<80 14 (10.9%) 9 (13.6%) 0.58 23 (11.9%)
>=80 114 (89.1%) 57 (86.4%) 171 (88.1%)
Missing 4 4 8
Karnofsky score
<90 36 (28.1%) 28 (42.4%) 0.045 64 (33%)
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close attention. Expert opinion suspects that it is widely
underdiagnosed [12], and our results strongly suggest that
to be the case, with up to 27% of deaths from MOF of
unknown origin being attributable to previously undiag-
nosed VOD/SOS. Furthermore, we do not believe this to be
a sequelae of underreporting, as our data show that most
cases were not reported by centers even after explicitly
asked through questionnaires while also considering the fact
that both VOD/SOS and MOF are available in the registry
under secondary causes of death (Supplementary Table 1).
This is extremely relevant considering the fact that appro-
priate treatment with defibrotide is readily available [8], and
makes a stronger case for its use as prophylaxis for high-
risk patients [9, 10]. In fact, pooled data from 17 defibrotide
studies (n= 2598) have shown estimated Day+100 survival
rates around 55% in patients treated with defibrotide [8].
Significant difference in survival however is noted between
patients developing MOF (44%) and those without MOF
(71%), highlighting the importance of prompt treatment
before progression of the disease and increased mortality
[8]. In addition, clinicians should recognize the existence of
late onset and anicteric VOD/SOS, and the need for its
prompt treatment with defibrotide and other measures
beyond the immediate post-transplant period.
Known risk factors for VOD/SOS such as advanced
disease beyond CR1, low performance status at transplant,
and the presence of pre-existing hepatic comorbidity or use
of hepatoxic drugs were significantly more common in
patients with VOD/SOS. Also, importantly, the use of
haploidentical and CB grafts which were possibly con-
founded by the consistent use of the highly hepatotoxic
MMF for GVHD prophylaxis in these settings were sig-
nificantly associated with increased VOD/SOS risk. The use
of other GVHD prophylactic drugs might therefore be more
appropriate to limit the incidence of VOD/SOS in extremely
high-risk patients [19, 20]. It is interesting to note that
although MAC conditioning and the use of TBI are usually
associated with increased VOD/SOS incidence [21], we did
not observe any significant effect. The use of FLAMSA
conditioning was more prevalent in the VOD/SOS group
however (20% vs 5%), which could have masked the
expected advantage of RIC conditioning.
VOD/SOS can develop at any time post-transplant, but it
is classically considered an early complication observed
within 3 weeks of alloHCT [1, 3]. While the median VOD/
SOS related MOF survival was dramatically lower than that
of non-VOD/SOS related MOF (61 days vs 128 days), it is
important to note that the majority of missed cases occurred
Table 1 (continued)
no VOD (n= 132) VOD (n= 70) P value Population
(n= 202)
>=90 92 (71.9%) 38 (57.6%) 130 (67%)
Missing 4 4 8
Comorbidity Index
0 66 (69.5%) 31 (58.5%) 0.12 97 (65.5%)
1 or 2 11 (11.6%) 13 (24.5%) 24 (16.2%)
>= 3 18 (18.9%) 9 (17%) 27 (18.2%)
Missing 37 17 54
Hepatic comorbidity
No 81 (96.4%) 34 (79.1%) 0.003 115 (91%)
Yes 3 (3.6%) 9 (20.9%) 12 (9%)
Missing 48 27 75
Obesity
No 110 (93.2%) 53 (89.8%) 0.43 163 (92.1%)
Yes 8 (6.8%) 6 (10.2%) 14 (7.9%)
Missing 14 11
Gentuzumab before transplant
No 130 (98.5%) 64 (91.4%) 0.022 194 (96%)
Yes 2 (1.5%) 6 (8.6%) 8 (4%)
Hepatic comorbidity or Gentuzumab before transplant
No 79 (94%) 32 (68.1%) < 0.0001 111 (85%)
Yes 5 (6%) 15 (31.9%) 20 (15%)
Missing 48 23 71
VOD veno-occlusive disease, Ph Philadelphia, CR complete remission.
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Table 2 Transplant characteristics & outcome comparison between VOD-related and non-VOD-related MOF.
no VOD (n= 132) VOD (n= 70) P value Population
(n= 202)
Year of transplant
median (min-max) 2015 (2010–2018) 2015 (2010–2018) 0.56 2015 (2010–2018)
Total number of alloHCTs per center
median (range) 368 (50–1469) 446 (50–1469) 0.77
Number of this transplant
First 117 61 0.75 178 (88.1%)
Second 15 (11.4%) 9 (12.9%) 24 (11.9%)
Donor
MSD 33 (25.2%) 16 (22.9%) 49 (24.4%)
UD 10/10 54 (41.2%) 19 (27.1%) 73 (36.3%)
UD 9/10 20 (15.3%) 10 (14.3%) 30 (14.9%)
UD 8/10 2 (1.5%) 2 (2.9%) 4 (2%)
UD uk 5 (3.8%) 4 (5.7%) 9 (4.5%)
Haploidentical 14 (10.7%) 9 (12.9%) 23 (11.4%)
Cord blood 3 (2.3%) 10 (14.3%) 13 (6.5%)
missing 1 0 1
MSD/UD 114 (87%) 51 (72.9%) 0.013 165 (82%)
Haplo/CB 17 (13%) 19 (27.1%) 36 (18%)
Cell source
BM 11 (8.3%) 5 (7.1%) 0.007 16 (7.9%)
PB 115 (87.1%) 54 (77.1%) 169 (83.7%)
BM+ PB 2 (1.5%) 0 (0%) 2 (1%)
CB 0 (0%) 4 (5.7%) 4 (2%)
Double CB 3 (2.3%) 6 (8.6%) 9 (4.5%)
BM+CB 1 (0.8%) 0 (0%) 1 (0.5%)
PB+ CB 0 (0%) 1 (1.4%) 1 (0.5%)
ex-vivo T-cell depletion
No 116 (89.9%) 63 (91.3%) 0.75 179 (90.4%)
Yes 13 (10.1%) 6 (8.7%) 19 (9.6%)
missing 3 1 4
In-vivo T-cell depletion
No 56 (43.1%) 37 (52.9%) 0.19 93 (46.5%)
Yes 74 (56.9%) 33 (47.1%) 107 (53.5%)
missing 2 0 2
No 56 (43.1%) 37 (52.9%) 0.37 93 (46.5%)
ATG 69 (53.1%) 32 (45.7%) 101 (50.5%)
Campath 5 (3.8%) 1 (1.4%) 6 (3%)
missing 2 0 2
Conditioning
MAC 75 (56.8%) 40 (57.1%) 0.96 115 (56.9%)
RIC 57 (43.2%) 30 (42.9%) 87 (43.1%)
BuCy 16 (12.3%) 9 (12.9%) 25 (12.5%)
BuFlu 34 (26.2%) 7 (10%) 41 (20.5%)
TBF 9 (6.9%) 6 (8.6%) 15 (7.5%)
FluMel 13 (10%) 6 (8.6%) 19 (9.5%)
TreoFlu 2 (1.5%) 3 (4.3%) 5 (2.5%)
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Table 2 (continued)
no VOD (n= 132) VOD (n= 70) P value Population
(n= 202)
FLAMSA 7 (5.4%) 14 (20%) 21 (10.5%)
TBI 35 (26.9%) 21 (30%) 56 (28%)
Other 14 (10.8%) 4 (5.7%) 18 (9%)
missing 2 0 2
GVHD prevention
CSA 28 (21.5%) 13 (18.6%) 0.22 41 (20.5%)
CSA+MTX+MMF 56 (43.1%) 22 (31.4%) 78 (39%)
MTX+ Tacrolimus 4 (3.1%) 1 (1.4%) 5 (2.5%)
csa+mmf+tacro 27 (20.8%) 23 (32.9%) 50 (25%)
CSA+ Tacrolimus 0 (0%) 1 (1.4%) 1 (0.5%)
CSA+MTX+MMF 2 (1.5%) 4 (5.7%) 6 (3%)
MMF+ Tacrolimus 6 (4.6%) 5 (7.1%) 11 (5.5%)
MMF+ Sirolimus 1 (0.8%) 0 (0%) 1 (0.5%)
CSA+MMF+
Tacrolimus
1 (0.8%) 0 (0%) 1 (0.5%)
Tacrolimus+Sirolimus 2 (1.5%) 1 (1.4%) 3 (1.5%)
Other 3 (2.3%) 0 (0%) 3 (1.5%)
missing 2 0 2
MMF for GVHD prevention
No 92 (70.8%) 38 (54.3%) 0.02 130 (65%)
Yes 38 (29.2%) 32 (45.7%) 70 (35%)
missing 2 0 2
MTX for GVHD prevention
No 68 (52.3%) 42 (60%) 0.3 110 (55%)
Yes 62 (47.7%) 28 (40%) 90 (45%)
missing 2 0 2
acute GVHD
Grade I 8 (6.5%) 3 (4.5%) 0.009 11 (5.8%)
Grade II 24 (19.5%) 7 (10.4%) 31 (16.3%)
Grade III 21 (17.1%) 3 (4.5%) 24 (12.6%)
Grade IV 12 (9.8%) 14 (20.9%) 26 (13.7%)
Present, grade unknown 2 (1.6%) 0 (0%) 2 (1.1%)
No aGvHD 56 (45.5%) 40 (59.7%) 96 (50.5%)
missing 9 3 12
acute GVHD II-IV
No 64 (52.9%) 43 (64.2%) 0.13 107 (56.9%)
Yes 57 (47.1%) 24 (35.8%) 81 (43.1%)
missing 11 3 14
acute GVHD III-IV
No 88 (72.7%) 50 (74.6%) 0.78 138 (73.4%)
Yes 33 (27.3%) 17 (25.4%) 50 (26.6%)
missing 11 3 14
chronic GVHD
No 100 (78.1%) 58 (82.9%) 0.43 158 (79.8%)
Yes 28 (21.9%) 12 (17.1%) 40 (20.2%)
missing 4 0 4







Reported late EBMT n=6
Reported classic EBMT / baltimore n=8
Reported modified seattle only n=3






Fig. 1 VOD diagnosis per scoring system. VOD Veno-occlusive disease, EBMT European Society for Blood and Marrow Transplantation.
Table 2 (continued)
no VOD (n= 132) VOD (n= 70) P value Population
(n= 202)
GVHD (acute ± chronic)
No 61 (46.2%) 37 (52.9%) 0.37 98 (48.5%)
Yes 71 (53.8%) 33 (47.1%) 104 (51.5%)
VOD prophylaxis
No 93 (71.0%) 43 (61.4%) 0.17 136 (67.7%)
Yes 38 (29.0%) 27 (38.6%) 65 (32.3%)
missing 1 0 1
Defibrotide 0 1 (3.8%) 1 (1.8%)
Ursodiol 11 (35.5%) 17 (65.4%) 28 (49.1%)
Heparin 11 (35.5%) 3 (11.5%) 14 (24.6%)
Other 1 (3.2%) 1 (3.8%) 2 (3.5%)
Defibrotide+Ursodiol 1 (3.2%) 0 1 (1.8%)
Heparin+Ursodiol 6 (19.4%) 3 (11.5%) 9 (15.8%)
Heparin+Ursodiol+
Other
1 (3.2%) 1 (3.8%) 2 (3.5%)
missing 7 1 8
Relapse
No 97 (73.5%) 59 (84.3%) 0.082 156 (77%)
Yes 35 (26.5%) 11 (15.7%) 46 (23%)
Survival time (days)






VOD veno-occlusive disease, MSD matched sibling donor, UD unrelated donor, BM bone marrow, PB peripheral blood, CB cord blood, MAC
myeloablative conditioning, RIC reduced intensity conditioning, TBI total body irradiation, CSA cyclosporine, MTX methotrexate, MMF
mycophenolate mofetil.
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well beyond the 3-week period, and even months after
transplant. This concept might therefore be behind the
oversight of VOD/SOS diagnosis, as a high level of clinical
attention is required to make this diagnosis, further
emphasizing the importance of the EBMT criteria for late
VOD/SOS extending beyond the traditional window [3].
Finally, the only consistent criterion suspicious of VOD/
SOS was an elevated bilirubin level present in 87% of
patients, others, such as ascites and hepatomegaly being pre-
sent in only around half of diagnosed patients. These findings
further highlight the heterogeneity of the disease presentation.
The main limitations of this study revolve around its ret-
rospective nature. In fact, our ability to apply the VOD/SOS
scoring criteria was limited by the availability of provided
data and is therefore potentially underreported. Furthermore,
very limited data was available to confirm or refute alternative
hypotheses of MOF-related death, such as the original dis-
ease, sepsis, GVHD, and treatment toxicities to name a few,
as the diagnosis of MOF was provided by centers. Finally, no
post-mortem pathology was available to confirm the VOD/
SOS diagnosis in patients that fit its criteria.
Conclusion
Our study is the first of its kind to investigate the hidden
incidence of VOD/SOS post-alloHCT as an underlying
cause of MOF. Our results suggest that VOD/SOS related
MOF is a widely under-reported cause of death, accounting
for around 27% of deaths attributed to MOF of unknown
origin with no previous VOD/SOS diagnosis. Furthermore,
it is highly suggested that patients with VOD/SOS related
MOF have a far worse outcome with a significantly lower
survival, which is attributable to both the relatively early
incidence of VOD/SOS post-transplant and its highly
accelerated progression and dismal course if untreated.
Patient presentations however were also frequently con-
sistent with a VOD/SOS diagnosis well beyond the classi-
cally defined 3-week post-transplant window, which could
explain the oversight of this entity usually considered an
early transplant complication. While the MOF concept is a
widely used cause of death post-alloHCT, having precise
categorization of cause-specific death from MOF should
allow not only for better understanding of entities such as
VOD/SOS, but also for disease-specific therapeutic inter-
ventions such as defibrotide which would greatly contribute
to improved patient outcome.
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